skip to main content

News Archive

Date: 05/26/2022
Men with advanced prostate cancer taking abiraterone or enzalutamide plus hormone therapy were at higher risk of serious medical issues than their peers undergoing hormone therapy alone.
Date: 05/20/2022
The Rogel Cancer Center has recently appointed four faculty members to named professorships. A named professorship is the highest honor a department or center can bestow upon a faculty member. Professorships are made possible by the generosity of donors.
Date: 05/16/2022
In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma. Cancers shrunk in 80% of the 20 patients on the clinical trial with marginal zone lymphoma, with a fifth experiencing complete remission.
Date: 05/02/2022
In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cancer.
Date: 04/28/2022
The University of Michigan Rogel Cancer Center will provide funding support to 12 exceptional faculty researchers, 2 early career clinical researchers and six medical and graduate students. In addition, the center has launched a new program for Rogel Scholars in Cancer Health Equity, to support two faculty members who are working to address the cancer burden in historically underserved or excluded populations.
Date: 04/25/2022
By using an artificial intelligence-based system, researchers improved doctors' assessment of whether patients with bladder cancer had a complete response to chemotherapy before undergoing a radical cystectomy (bladder cancer removal surgery).
Date: 04/20/2022
Noninvasive sound technology developed at the University of Michigan breaks down liver tumors in rats, kills cancer cells and spurs the immune system to prevent further spread—an advance that could lead to improved cancer outcomes in humans.
Date: 04/20/2022
The Emerging Leaders Council (ELC) is comprised of 15 early career faculty members interested in taking a larger role in the cancer center. Candidates are selected by the SLC and serve 3-year terms. The council is led by a chair, and two co-chairs elected by the ELC members to serve one-year terms.
Date: 04/12/2022
A team at the University of Michigan Health Rogel Cancer Center, in partnership with the statewide Michigan Radiation Oncology Quality Consortium, or MROQC, lung cancer collaborative, co-led by Shruti Jolly, M.D., and Peter Paximadis, M.D., of Spectrum Health Lakeland in St. Joseph, Michigan, found that raising awareness about the risk of radiation exposure to the heart and standardizing cardiac exposure limits reduced the average dose to the heart by 15% and reduced the number of patients receiving the highest heart doses by half without minimizing tumor treatment or increasing dosage to other at-risk organs in the chest.
Date: 03/29/2022
More than 40 Rogel Cancer Center-led research efforts will be presented during the AACR Annual Meeting 2022, which runs April 8-13 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and online.